Catalent, Inc. (NYSE:CTLT) Shares Sold by North Star Asset Management Inc.

North Star Asset Management Inc. trimmed its position in Catalent, Inc. (NYSE:CTLT) by 29.3% in the second quarter, Holdings Channel reports. The firm owned 39,783 shares of the company’s stock after selling 16,467 shares during the quarter. North Star Asset Management Inc.’s holdings in Catalent were worth $2,237,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nomura Holdings Inc. raised its holdings in shares of Catalent by 149.4% during the fourth quarter. Nomura Holdings Inc. now owns 11,487,342 shares of the company’s stock worth $516,126,000 after purchasing an additional 6,881,914 shares during the period. Norges Bank bought a new stake in shares of Catalent in the 4th quarter worth approximately $116,021,000. Capital World Investors grew its stake in Catalent by 6.1% during the 4th quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock worth $857,264,000 after buying an additional 1,098,474 shares during the last quarter. Magnetar Financial LLC acquired a new stake in Catalent in the first quarter worth $56,429,000. Finally, Cadian Capital Management LP lifted its stake in Catalent by 14.3% in the fourth quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock valued at $272,473,000 after buying an additional 759,600 shares during the last quarter.

Analysts Set New Price Targets

Several analysts recently weighed in on CTLT shares. Royal Bank of Canada reiterated a “sector perform” rating and issued a $63.50 price objective on shares of Catalent in a research report on Thursday, July 11th. William Blair reiterated a “market perform” rating on shares of Catalent in a research report on Tuesday. StockNews.com started coverage on Catalent in a research report on Monday, September 2nd. They issued a “sell” rating on the stock. Finally, Barclays boosted their price target on Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research report on Friday, June 28th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, Catalent presently has an average rating of “Hold” and a consensus target price of $58.08.

Insider Buying and Selling

In other Catalent news, CFO Matti Masanovich sold 2,993 shares of the business’s stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $56.74, for a total transaction of $169,822.82. Following the sale, the chief financial officer now owns 33,871 shares in the company, valued at approximately $1,921,840.54. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, CFO Matti Masanovich sold 2,993 shares of the firm’s stock in a transaction on Monday, July 8th. The stock was sold at an average price of $56.74, for a total value of $169,822.82. Following the completion of the sale, the chief financial officer now owns 33,871 shares of the company’s stock, valued at $1,921,840.54. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Scott Gunther sold 666 shares of the company’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.55, for a total value of $39,660.30. Following the transaction, the senior vice president now directly owns 39,635 shares in the company, valued at $2,360,264.25. The disclosure for this sale can be found here. Insiders have sold 13,409 shares of company stock worth $782,923 in the last three months. 0.31% of the stock is currently owned by insiders.

Catalent Trading Down 0.6 %

Shares of NYSE:CTLT opened at $60.03 on Friday. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.77 and a current ratio of 2.51. The stock has a market capitalization of $10.86 billion, a price-to-earnings ratio of -9.84, a PEG ratio of 2.52 and a beta of 1.16. Catalent, Inc. has a 1-year low of $31.80 and a 1-year high of $61.20. The company has a 50 day moving average price of $58.88 and a 200 day moving average price of $57.07.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.